NCT00642252

Brief Summary

The primary goals of this project are to determine the anticaries benefits of a prototype multi-mineral mouthrinse containing 225 ppm fluoride and 30 ppm of a Ca through the remineralization of enamel white-spots (non-cavitated lesions). The selection of patients with pre-existing white-spot lesions will permit an opportunity to evaluate the efficacy of the multi-mineral mouthrinse in reminerzalizing and/or inhibiting progression of enamel white-spot lesions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Jan 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 17, 2008

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 25, 2008

Completed
3.8 years until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

March 25, 2015

Status Verified

March 1, 2015

Enrollment Period

1.9 years

First QC Date

March 17, 2008

Last Update Submit

March 23, 2015

Conditions

Keywords

remineraliationpre-existing white-spot (non-cavitated) enamel lesions

Outcome Measures

Primary Outcomes (1)

  • Remineralization of non-cavitated enamel lesions.

    baseline, 6, 12, 18, 24 months

Study Arms (2)

B

EXPERIMENTAL

226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse

Drug: Fluoride

A

ACTIVE COMPARATOR

ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)

Drug: Fluoride

Interventions

Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.

Also known as: ACT fluoride mouthrinse
A

Eligibility Criteria

Age13 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • To participate in this study, panelists will be required to meet the following criteria:
  • Subjects must be 13 - 65 years of age;
  • Subjects must read and sign the Informed Consent prior to initiation of study procedures. All subjects will receive a copy of the signed Informed Consent;
  • Subjects must have a reasonable functional dentition, without a large number of missing teeth, and teeth #'s 22-27 present;
  • Have normal salivary gland function (unstimulated whole salivary flow rate equal to or greater than 0.25 ml/min and paraffin stimulated whole salivary flow rate equal to or at least 1.0 ml/min);
  • Subjects must be willing to participate in the study, be able to follow the study directions, be willing to return for all specified visits at their appointed time, and to use the product as per instructions;
  • Subjects must be in good general health based on medical history and oral soft and hard tissue examination.

You may not qualify if:

  • Criteria that will not permit participation in this study will be as follows:
  • Any subject who is pregnant or lactating - based on oral interview only - as pregnancy may interfere with the outcome of the study;
  • Any subject who has a systemic health condition such as diabetes that could affect the outcome of the study at the discretion of the examiner;
  • Any subject who has an oral condition, such as excessive, untreated dental caries, periodontal disease, chronic dental neglect, or any oral pathology including xerostomia determined by oral examination and subject history that in the opinion of the dental examiner could affect the outcome of the study;
  • Any subject who has full dentures, or full orthodontic appliances. No use of nightguards will be permitted during the study period;
  • Any subject who uses oral care products (other than those permitted) during the treatment or wash-out periods;
  • Any subject with an immunological disorders such as HIV positive, AIDS, and systemic Lupus Erythematosis;
  • Any subject concurrently participating in another clinical study;
  • Any subject currently taking antibiotics or other medications, which in the opinion of the Investigator/Examiner might influence the study outcome;
  • Any subject with a history of sensitivity to oral products or allergies to ingredients in the products;
  • Any subject who fails to keep any of their scheduled appointments.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Crispus Attucks Medical Magnet High School

Indianapolis, Indiana, 46202, United States

Location

MeSH Terms

Conditions

Dental Caries

Interventions

Fluorides

Condition Hierarchy (Ancestors)

Tooth DemineralizationTooth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

AnionsIonsElectrolytesInorganic ChemicalsHydrofluoric AcidFluorine Compounds

Study Officials

  • George K Stookey, PhD

    Indiana Nanotech

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Managing Member

Study Record Dates

First Submitted

March 17, 2008

First Posted

March 25, 2008

Study Start

January 1, 2012

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

March 25, 2015

Record last verified: 2015-03

Locations